No Prescription |
 |
 | ||
|
Ursofalk URSO |
|
| ||
No Prescription » Prescription Drugs 16 » Ursofalk URSO Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Category Anticholelithic Description Ursodiol (ur-so-DYE-ole) is used in the treatment of gallstone disease. Ursofalk tablets are indicated for the treatment of patients with primary biliary cirrhosis. SODIOL (Systemic) Some commonly used brand names are: In the U.S. Actigall URSO 250 In Canada URSO Ursofalk Other commonly used names are ursodeoxycholic acid and UDCA . Buy Ursofalk URSO and other Prescription Drugs 16 products online at Medstore. 3733
About Ursofalk URSO: Product Type: Prescription Drugs 16 Ursofalk ( URSO URSODIOL Generic Ursodexycholic acid ) Ursofalk (URSO URSODIOL Generic Ursodexycholic acid) URSO URSODIOL Generic Ursodexycholic acid 250mg 100 Capsules URSO URSODIOL Generic Ursodexycholic acid Ursofalk
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
